Stocks
Arrowhead Pharmaceuticals (ARWR) EBITDA margin US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | 38.9% | -99.1% | -101.8% | -73.4% | -78.2% | -1 256% | ||
| Changes by years, y/y, % | +359pp | -138pp | -3pp | +28pp | -5pp | -24.6% | |||
Arrowhead Pharmaceuticals. EBITDA margin, %
Arrowhead Pharmaceuticals. EBITDA margin, changes, pp
Arrowhead Pharmaceuticals (ARWR) EBITDA margin US GAAP (quarter values) |
||||||||
| 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
| EBITDA margin, % | ? | -67.4% | 37.9% | -600.0% | -620.4% | -3 634% | -1 256% | |
| Changes by years, y/y, % | +152pp | +9pp | -383pp | -355pp | -3 567pp | |||
| Changes by quarters, q/q, % | +198pp | +105pp | -638pp | -20pp | -3 014pp | |||
